Advertisement

Topics

Phase III testing of argenx's thrombocytopenia candidate planned

06:36 EDT 18 Sep 2018 | SmartBrief

Argenx announced plans for a late-stage study to test its candidate ARGX-113, or IV efgartigimod, indicated for the treatment -More

Original Article: Phase III testing of argenx's thrombocytopenia candidate planned

NEXT ARTICLE

More From BioPortfolio on "Phase III testing of argenx's thrombocytopenia candidate planned"

Advertisement
Quick Search
Advertisement
Advertisement